Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.

Gauthier G, Eibl JK, Marsh DC.

Drug Alcohol Depend. 2018 Oct 1;191:1-5. doi: 10.1016/j.drugalcdep.2018.04.029. Epub 2018 May 31.

PMID:
30064001
2.

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder.

Palis H, Marchand K, Karamouzian M, MacDonald S, Harrison S, Guh D, Lock K, Brissette S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Addict Behav Rep. 2018 Mar 27;7:82-89. doi: 10.1016/j.abrep.2018.03.005. eCollection 2018 Jun.

3.

Characterizing the Use of Telepsychiatry for Patients with Opioid Use Disorder and Cooccurring Mental Health Disorders in Ontario, Canada.

LaBelle B, Franklyn AM, Pkh Nguyen V, Anderson KE, Eibl JK, Marsh DC.

Int J Telemed Appl. 2018 Feb 11;2018:7937610. doi: 10.1155/2018/7937610. eCollection 2018.

4.

Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.

Bansback N, Guh D, Oviedo-Joekes E, Brissette S, Harrison S, Janmohamed A, Krausz M, MacDonald S, Marsh DC, Schechter MT, Anis AH.

Addiction. 2018 Jul;113(7):1264-1273. doi: 10.1111/add.14171. Epub 2018 Mar 28.

PMID:
29589873
5.

Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.

Dunn KE, Brands B, Marsh DC, Bigelow GE.

Psychopharmacology (Berl). 2018 Apr;235(4):971-981. doi: 10.1007/s00213-017-4814-3. Epub 2017 Dec 21.

PMID:
29270641
6.

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada.

Franklyn AM, Eibl JK, Gauthier GJ, Marsh DC.

PLoS One. 2017 Nov 8;12(11):e0187633. doi: 10.1371/journal.pone.0187633. eCollection 2017.

7.

The opioid crisis: past, present and future policy climate in Ontario, Canada.

Morin KA, Eibl JK, Franklyn AM, Marsh DC.

Subst Abuse Treat Prev Policy. 2017 Nov 2;12(1):45. doi: 10.1186/s13011-017-0130-5.

8.

The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada.

Franklyn AM, Eibl JK, Gauthier GJ, Pellegrini D, Lightfoot NE, Marsh DC.

Int J Drug Policy. 2017 Oct;48:1-8. doi: 10.1016/j.drugpo.2017.05.044. Epub 2017 Jun 27.

PMID:
28666202
9.

Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.

Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Rev. 2018 Jan;37(1):137-146. doi: 10.1111/dar.12573. Epub 2017 Jun 8.

PMID:
28593748
10.

The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study.

Rosic T, Naji L, Bawor M, Dennis BB, Plater C, Marsh DC, Thabane L, Samaan Z.

Neuropsychiatr Dis Treat. 2017 May 24;13:1399-1408. doi: 10.2147/NDT.S129480. eCollection 2017.

11.

The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.

Eibl JK, Gauthier G, Pellegrini D, Daiter J, Varenbut M, Hogenbirk JC, Marsh DC.

Drug Alcohol Depend. 2017 Jul 1;176:133-138. doi: 10.1016/j.drugalcdep.2017.01.048. Epub 2017 May 17.

12.

Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.

Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Subst Abuse Treat Prev Policy. 2017 May 19;12(1):25. doi: 10.1186/s13011-017-0110-9.

13.

The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight.

Eibl JK, Morin K, Leinonen E, Marsh DC.

Can J Psychiatry. 2017 Jul;62(7):444-450. doi: 10.1177/0706743717711167. Epub 2017 May 19. Review.

14.

Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.

Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Depend. 2017 Jul 1;176:55-62. doi: 10.1016/j.drugalcdep.2017.02.021. Epub 2017 May 10.

PMID:
28521199
15.

Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences.

Zielinski L, Bhatt M, Sanger N, Plater C, Worster A, Varenbut M, Daiter J, Pare G, Marsh DC, Desai D, MacKillop J, Steiner M, McDermid Vaz S, Thabane L, Samaan Z.

Biol Sex Differ. 2017 Mar 30;8:8. doi: 10.1186/s13293-017-0130-1. eCollection 2017.

16.

Erratum to: The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.

Franklyn AM, Eibl JK, Gauthier G, Pellegrini D, Lightfoot NE, Marsh DC.

Harm Reduct J. 2017 Mar 28;14(1):15. doi: 10.1186/s12954-017-0140-7. No abstract available.

17.

The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone maintenance therapy.

Naji L, Dennis BB, Bawor M, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, MacKillop J, Thabane L, Samaan Z.

Addict Sci Clin Pract. 2017 Mar 28;12(1):9. doi: 10.1186/s13722-017-0074-0.

18.

The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.

Franklyn AM, Eibl JK, Gauthier G, Pellegrini D, Lightfoot NE, Marsh DC.

Harm Reduct J. 2017 Jan 26;14(1):6. doi: 10.1186/s12954-017-0134-5. Erratum in: Harm Reduct J. 2017 Mar 28;14 (1):15.

19.

Producing a socially accountable medical school: AMEE Guide No. 109.

Boelen C, Pearson D, Kaufman A, Rourke J, Woollard R, Marsh DC, Gibbs T.

Med Teach. 2016 Nov;38(11):1078-1091. Epub 2016 Sep 9.

PMID:
27608933
20.

Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the 'other epidemic'.

Eibl JK, Morin-Taus KA, Marsh DC.

Subst Abuse Treat Prev Policy. 2016 Sep 20;11(1):33. doi: 10.1186/s13011-016-0076-z.

21.

A Prospective Study to Investigate Predictors of Relapse among Patients with Opioid Use Disorder Treated with Methadone.

Naji L, Dennis BB, Bawor M, Plater C, Pare G, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Thabane L, Samaan Z.

Subst Abuse. 2016 Apr 10;10:9-18. doi: 10.4137/SART.S37030. eCollection 2016.

22.

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, Marsh DC, Schechter MT.

JAMA Psychiatry. 2016 May 1;73(5):447-55. doi: 10.1001/jamapsychiatry.2016.0109.

PMID:
27049826
23.

Pain and Opioid Addiction: A Systematic Review and Evaluation of Pain Measurement in Patients with Opioid Dependence on Methadone Maintenance Treatment.

Dennis BB, Bawor M, Paul J, Plater C, Pare G, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Thabane L, Samaan Z.

Curr Drug Abuse Rev. 2016;9(1):49-60. Review.

PMID:
27021147
24.

Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment.

Dennis BB, Roshanov PS, Bawor M, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.

Pain Physician. 2016 Jan;19(1):E181-95.

25.

A critical hybrid realist-outcomes systematic review of relationships between medical education programmes and communities: BEME Guide No. 35.

Ellaway RH, O'Gorman L, Strasser R, Marsh DC, Graves L, Fink P, Cervin C.

Med Teach. 2016;38(3):229-45. doi: 10.3109/0142159X.2015.1112894. Epub 2015 Dec 8. Review.

PMID:
26646982
26.

Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study.

Bawor M, Dennis BB, Varenbut M, Daiter J, Marsh DC, Plater C, Worster A, Steiner M, Anglin R, Pare G, Desai D, Thabane L, Samaan Z.

Biol Sex Differ. 2015 Nov 10;6:21. doi: 10.1186/s13293-015-0038-6. eCollection 2015.

27.

Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria.

Dennis BB, Roshanov PS, Naji L, Bawor M, Paul J, Plater C, Pare G, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Samaan Z, Thabane L.

Trials. 2015 Oct 21;16:475. doi: 10.1186/s13063-015-0942-4. Review.

28.

Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada.

Eibl JK, Gomes T, Martins D, Camacho X, Juurlink DN, Mamdani MM, Dhalla IA, Marsh DC.

J Addict Med. 2015 Nov-Dec;9(6):440-6. doi: 10.1097/ADM.0000000000000156.

29.

Sex differences in outcomes of methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis.

Bawor M, Dennis BB, Bhalerao A, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Steiner M, Anglin R, Pare G, Thabane L, Samaan Z.

CMAJ Open. 2015 Jul 17;3(3):E344-51. doi: 10.9778/cmajo.20140089. eCollection 2015 Jul-Sep.

30.

Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study.

Bawor M, Dennis BB, Tan C, Pare G, Varenbut M, Daiter J, Plater C, Worster A, Marsh DC, Steiner M, Anglin R, Desai D, Thabane L, Samaan Z.

Addict Sci Clin Pract. 2015 Oct 6;10:19. doi: 10.1186/s13722-015-0040-7.

31.

Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.

Dennis BB, Bawor M, Naji L, Chan CK, Varenbut J, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.

Subst Abuse. 2015 Sep 10;9:59-80. doi: 10.4137/SART.S30120. eCollection 2015. Review.

32.

Putting communities in the driver's seat: the realities of community-engaged medical education.

Strasser R, Worley P, Cristobal F, Marsh DC, Berry S, Strasser S, Ellaway R.

Acad Med. 2015 Nov;90(11):1466-70. doi: 10.1097/ACM.0000000000000765.

PMID:
26017354
33.

The impact of chronic pain on opioid addiction treatment: a systematic review protocol.

Dennis BB, Bawor M, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.

Syst Rev. 2015 Apr 16;4:49. doi: 10.1186/s13643-015-0042-2. Review.

34.

Testosterone suppression in opioid users: a systematic review and meta-analysis.

Bawor M, Bami H, Dennis BB, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC, Steiner M, Anglin R, Coote M, Pare G, Thabane L, Samaan Z.

Drug Alcohol Depend. 2015 Apr 1;149:1-9. doi: 10.1016/j.drugalcdep.2015.01.038. Epub 2015 Feb 8. Review.

35.
36.

Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.

Oviedo-Joekes E, Sordo L, Guh D, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Addict Behav. 2015 Feb;41:81-6. doi: 10.1016/j.addbeh.2014.10.003. Epub 2014 Oct 7.

37.

Evaluation of clinical and inflammatory profile in opioid addiction patients with comorbid pain: results from a multicenter investigation.

Dennis BB, Samaan MC, Bawor M, Paul J, Plater C, Pare G, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Thabane L, Samaan Z.

Neuropsychiatr Dis Treat. 2014 Nov 19;10:2239-47. doi: 10.2147/NDT.S72785. eCollection 2014.

38.

A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trial.

Oviedo-Joekes E, Marchand K, Lock K, Chettiar J, Marsh DC, Brissette S, Anis AH, Schechter MT.

Addict Sci Clin Pract. 2014 Sep 29;9:21. doi: 10.1186/1940-0640-9-21.

39.

Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence.

Mistry CJ, Bawor M, Desai D, Marsh DC, Samaan Z.

Curr Psychiatry Rev. 2014 May;10(2):156-167.

40.

The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.

Dennis BB, Naji L, Bawor M, Bonner A, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Samaan Z, Thabane L.

Syst Rev. 2014 Sep 19;3:105. doi: 10.1186/2046-4053-3-105. Review.

41.

Problems with the identification of 'problematic' cannabis use: examining the issues of frequency, quantity, and drug use environment.

Asbridge M, Duff C, Marsh DC, Erickson PG.

Eur Addict Res. 2014;20(5):254-67. doi: 10.1159/000360697. Epub 2014 Aug 28. Review.

42.

Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study.

Samaan Z, Bawor M, Dennis BB, Plater C, Varenbut M, Daiter J, Worster A, Marsh DC, Tan C, Desai D, Thabane L, Pare G.

Neuropsychiatr Dis Treat. 2014 Aug 19;10:1503-8. doi: 10.2147/NDT.S66234. eCollection 2014.

43.

Methadone induces testosterone suppression in patients with opioid addiction.

Bawor M, Dennis BB, Samaan MC, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Steiner M, Anglin R, Coote M, Pare G, Thabane L, Samaan Z.

Sci Rep. 2014 Aug 26;4:6189. doi: 10.1038/srep06189.

44.

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.

Oviedo-Joekes E, Guh D, Marchand K, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Subst Abuse Treat Prev Policy. 2014 Jun 8;9:23. doi: 10.1186/1747-597X-9-23.

45.

High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: results from a population-level retrospective cohort study.

Nosyk B, Fischer B, Sun H, Marsh DC, Kerr T, Rehm JT, Anis AH.

Am J Addict. 2014 May-Jun;23(3):257-64. doi: 10.1111/j.1521-0391.2014.12091.x.

46.
47.

A call for evidence-based medical treatment of opioid dependence in the United States and Canada.

Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, Wood E, Montaner JS.

Health Aff (Millwood). 2013 Aug;32(8):1462-9. doi: 10.1377/hlthaff.2012.0846.

48.

Changes in the characteristics and levels of comorbidity among new patients into methadone maintenance treatment program in British Columbia during its expansion period from 1998-2006.

Sharif B, Nosyk B, Sun H, Marsh DC, Anis A.

Subst Use Misuse. 2013 Jun;48(8):671-82. doi: 10.3109/10826084.2013.800119. Epub 2013 Jun 10.

49.

Transforming health professional education through social accountability: Canada's Northern Ontario School of Medicine.

Strasser R, Hogenbirk JC, Minore B, Marsh DC, Berry S, McCready WG, Graves L.

Med Teach. 2013 Jun;35(6):490-6. doi: 10.3109/0142159X.2013.774334. Epub 2013 Mar 15.

PMID:
23496120
50.

Sexual identity and drug use harm among high-risk, active substance users.

Chow C, Vallance K, Stockwell T, Macdonald S, Martin G, Ivsins A, Marsh DC, Michelow W, Roth E, Duff C.

Cult Health Sex. 2013;15(3):311-26. doi: 10.1080/13691058.2012.754054. Epub 2013 Jan 14.

PMID:
23311592

Supplemental Content

Loading ...
Support Center